Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys by Mouritsen, Annette et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated
with delayed pubarche in healthy boys
Mouritsen, Annette; Busch, Alexander Siegfried; Aksglaede, Lise; Rajpert-De Meyts, Ewa;
Juul, Anders
Published in:
Endocrine Connections
DOI:
10.1530/EC-18-0080
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Mouritsen, A., Busch, A. S., Aksglaede, L., Rajpert-De Meyts, E., & Juul, A. (2018). Deletion in the uridine
diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys. Endocrine
Connections, 7(3), 460-465. https://doi.org/10.1530/EC-18-0080
Download date: 03. Feb. 2020
7:3 460–465A Mouritsen et al. UGT2B17 and pubarche
RESEARCH
Deletion in the uridine diphosphate 
glucuronyltransferase 2B17 gene is associated 
with delayed pubarche in healthy boys
Annette Mouritsen1,2, Alexander Siegfried Busch1,2, Lise Aksglaede1,2, Ewa Rajpert-De Meyts1,2 and  
Anders Juul1,2
1Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
University of Copenhagen, Copenhagen, Denmark
Correspondence should be addressed to A S Busch: alexander.siegfried.busch@regionh.dk
Abstract
Objective: Only a few genetic loci are known to be associated with male pubertal events. 
The ability of excreting testosterone (T) and other steroids in the urine depends on 
sulfation and glucuronidation. One of several essential glucuronidases is encoded by the 
UGT2B17 gene. In a preliminary report, we found that homozygous deletion of UGT2B17 
in boys was associated with lower urinary excretion of T. We hypothesized that boys 
with a lower glucuronidation capacity may have altered androgen action and excretion 
affecting pubarche, as this represents a T-dependent event.
Design, participants and measures: 668 healthy boys (cross-sectional) aged 6.1–21.9 years 
(COPENHAGEN puberty study conducted from 2005 to 2006) were included. 65 of the 
boys where followed longitudinally every 6 months. Participants were genotyped for 
UGT2B17 copy number variation (CNV). Clinical pubertal staging including orchidometry, 
anthropometry and serum reproductive hormone levels.
Results: 59 of the 668 boys (8.8%) presented with a homozygous deletion of UGT2B17 
(del/del). These boys experienced pubarche at a mean age of 12.73 years (12.00–13.46) 
vs 12.40 years (12.11–12.68) in boys heterozygous for deletion of UGT2B17 (del/ins) 
vs 12.06 years (11.79–12.33) in boys with the wild-type genotype (ins/ins) (P = 0.029, 
corrected for BMI z-score). The effect accounted for 0.34 years delay per allele (95% CI: 
0.03–0.64). A comparable trend was observed for onset of testicular enlargement >3 mL 
but did not reach significance.
Conclusion: CNV of UGT2B17 is a factor contributing to the timing of male pubarche.
Introduction
Testosterone (T) promotes maturation of the male 
reproductive organs, development of secondary sex 
characteristics and production of sperm by the testes. In 
puberty in boys, pulsatile gonadotropin stimulation upon 
reactivation of the hypothalamic–pituitary–gonadal axis 
results in testicular enlargement >3 mL and secretion of 
T produced by the testicular Leydig cells (gonadarche). 
Furthermore, gradually increasing secretion of androgens 
including T produced by the adrenal glands is occurring 
from mid-childhood (adrenarche) resulting in pubic hair 
development (pubarche). T exerts its effects by binding 
to the androgen receptor (AR). Activation of the AR by T 
binding may vary and depends on the free biologically 
active T concentration. Thus, the biological activity of 
circulating T depends on the concentration of total T, 
albumin and sex hormone-binding globulin (SHBG), 
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the transendothelial transport to target tissues, as well 
as the peripheral conversion rate of T into Estradiol (E2) 
and dihydrotestosterone (DHT). Finally, T concentration 
depends on the clearance rate, determined by, conversion 
of T to its metabolites, conjugation capacity, as well 
as urinary excretion. The ability of excreting T and 
other steroids in the urine depends on sulfation and 
glucuronidation of steroids to water-soluble conjugates. 
One of the several essential glucuronidases is uridine 
diphosphate glucuronyltransferase 2B17, encoded by 
the UGT2B17 gene, and several studies observed a lower 
urinary excretion of T with unaltered or higher level in 
the blood in males with homozygous UGT2B17 (1, 2, 3). 
In a pilot study, we observed a significantly reduction of 
the urinary T:epitestosterone (E) ratio in UGT2B17 del/del 
boys, but without lower concentration of T in the blood 
(4). In vitro studies have suggested an inverse association 
between the level of UGT2B17 and the level of DHT (and 
other T metabolites) in local tissues (5).
We hypothesize that boys with lower glucuronidation 
of T due to a homozygous UGT2B17 deletion have altered 
T clearance, which may consequently influence the age at 
which boys develop androgen-dependent pubic hair.
Materials and methods
Subjects
Healthy boys (668 boys from 6.1 to 21.9  years of age) 
participating in the cross-sectional COPENHAGEN 
Puberty Study were included in the study (6, 7). Of the 
668 included boys, 65 were followed every six months for 
five years (2006–2010, median (range) 11 (2–15) visits per 
boy) in the longitudinal part of the study (6, 7). Other 
aspects of this study have previously been published 
(4, 8, 9, 10, 11, 12). The Copenhagen Puberty Study was 
approved by the local ethical committee (Videnskabsetiske 
Komité for Region Hovedstaden, # KF 01 282214 and # 
V200.1996/90). The study is registered in ClinicalTrials.
gov (NCT01411527).
Consent has been obtained from each participant and 
parents after full explanation of the purpose and nature of 
all procedures used.
Clinical examination
Pubertal stages were evaluated by clinical examination 
according to Marshall and Tanner (13, 14). All evaluations 
of puberty in boys were performed by one of 3 male 
pediatricians. Testicular volume (TV) was measured by 
palpation to the nearest mL using Prader’s orchidometer. In 
case of discrepancy between left and right side, the largest 
measurement was used for classification. Assessment 
of pubic hair staging was done by inspection. Onset of 
testicular enlargement was defined as development 
testicular volume >3 mL (TV > 3 mL). Pubarche was defined 
as pubic hair (PH) stage ≥ PH2. Pubertal onset was defined 
as TV > 3 mL or pubic hair stage > PH2.
Age at onset of pubic hair (PH2+) or testis volume 
>3 mL was assigned as the mean age between age at 
the first examination in stage 2 or >3 mL and the latest 
examination in stage 1 or ≤3 mL, respectively.
Genotyping
DNA was isolated from peripheral blood using a semi-
automatic nucleic acid isolation method, either on a 
QuickGene-810 apparatus (Fujifilm, Life Science Products, 
Tokyo, Japan) or Maxwell-16 (Promega Biotech AB), and 
quantified on a NanoDrop ND-1000 spectrophotometer 
(Saveen Werner AB, Malmö, Sweden). The analysis of 
UGT2B17 copy number variation (CNV) was performed 
by quantitative PCR on the Mx3000P platform 
(Stratagene, Cedar Creek, TX, USA), using primers specific 
for UGT2B17 and for the internal normalization gene 
GAPDH, as previously described in details (4).
Hormone analyses
Blood samples were drawn between 8:00 h and 10:00 h. 
The samples were clotted, centrifuged and serum was 
stored at −20°C until hormone analyses were performed.
Serum FSH and LH were measured by time-resolved 
immunofluorometric assays (Delfia; PerkinElmer) with 
detection limits of 0.06 and 0.05 IU/L for FSH and 
LH, respectively. Intra- and inter-assay coefficients of 
variation (CV) were less than 5% in both gonadotropin 
assays. Estradiol levels were determined by RIA (Pantex, 
Santa Monica, CA, USA) with detection limit of 18 pmol/L 
and the intra- and inter-assays CV were 7.5% and 12.3% 
respectively. SHBG was determined buy a time-resolved 
immunofluorescence assay (Delfia; Wallac Oy, Turku, 
Finland) with a detection limit of 0.20 nmol/L. Intra- and 
inter-assays CV were 5.8% and 6.4% respectively.
DHEAS, adione (androstenedione) and T in serum 
were quantified using a validated TurboFlow-LC–MS/MS 
method (15). The Adione:DHEAS ratio was calculated as 
adione (nmol/L) divided with DHEAS (nmol/L). Relative 
standard deviations for the quality control samples at the 
low and high concentration levels, respectively in that 
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period were: DHEAS, 7.1% and 8.3%; adione, 11.0% and 
11.1% and T, 10.0% and 5.7%. Limits of quantification 
(LOQ) were determined according to the International 
Conference on Harmonisation guidelines (ICH, 2005) 
and were DHEAS, 48 nmol/L; adione, 0.18 nmol/L and T, 
0.10 nmol/L.
Statistical analysis
Data are resented as medians and 25 and 75 percentiles 
and as means and 95% confidence interval (CI). For 
hormone levels below the LOQ, the LOQ divided by the 
square root of 2 was used.
In order to estimate the mean age (95% CI) at 
pubertal onset, we performed probit analyses (SAS; proc 
lifereg). This allowed integration of left-, right- and 
interval-censored observations and pubic hair status 
(PH2+) or testis volume >3 mL, yes/no as a binomial 
response variable. Longitudinal data of boys entering 
puberty during follow-up was included in the probit 
analyses (interval censored data). If a boy entered puberty 
between two examinations, the date between these 
examinations was used as interval-censored data. If a boy 
had not entered puberty at his last examination (or only 
examination if seen once), his age at examination was 
used as right censored data. If a boy had entered puberty 
at his first examination, his age at examination was used 
as left censored data.
The cohort was standardized by applying WHO age-
specific body mass index scores (BMI z-scores) (16). As 
longitudinal data were available in 65 boys, we calculated 
a mean of all individual BMI z-scores. Comparisons of 
hormone levels between groups were carried out using 
GLM Univariate using the SPSS software (version 19; 
SPSS). In the probit analyses, age at pubertal onset was 
adjusted for BMI z-score. Examinations above the age of 
19 years (n = 18) were not included into the analysis of 
pubertal onset, as the WHO age-specific body mass index 
scores is not specified for this age.
A P value ≤0.05 was considered statistically significant.
Results
Approximately one out of ten boys presented with the 
homozygous deletion of the UGT2B17 (del/del): 59 of 
the 668 boys in the cross-sectional study (8.8%) and 6 of 
the 65 boys in the longitudinal study (9.2%) (Table  1). 
Irrespective of UGT2B17 genotype, mean age at testicular 
enlargement >3 mL was 11.65  years (11.51–11.80, 
non-corrected) and 11.76 (11.62–11.90, corrected for 
BMI z-score) while mean age at pubarche was 12.16 
(11.96–12.36; non-corrected) and 12.26 (12.06–12.46, 
corrected for BMI z-score) (Fig. 1).
Pubic hair developed at a later age in boys with 
the UGT2B17 del/del genotype compared to the boys 
who were heterozygous and homozygous carriers of the 
UGT2B17 gene (del/ins) and (ins/ins). The UGT2B17  
del/del boys experienced pubarche (PH2+) at a mean age 
of 12.73 years (12.00–13.46) compared to a mean age of 
12.40 (12.11–12.68) in boys with the del/ins and a mean 
age of 12.06 (11.79–12.33) in boys with the ins/ins when 
corrected for BMI z-score (P = 0.029). The effect accounted 
for 0.34  years delay per allele (95% CI: 0.03–0.64). The 
comparisons were also statistical significant without 
correction for zBMI (P = 0.043; effect size: 0.32 years per 
allele; 95% CI: 0.00–0.65). Table 1 illustrates age at PH2+ in 
all three groups, with and without BMI z-score correction.
Although not statistically significant with and without 
BMI z-score correction (Table 1), we observed a later onset 
of testicular enlargement >3 mL in the boys with the 
homozygote deletion compared to the boys with the ins/del 
and the ins/ins genotype (12.09  years (11.54–12.64) 
vs 11.79 (11.58–11.99) and 11.69  years (11.50–11.89); 
Table 1 Age, zBMI, age at pubertal onset PH2+ (pubarche) and TV (testicular volume) >3 mL stratified by UGT2B17 genotype.
UGT2B17 genotype del/del (n = 59) del/ins (n = 309) ins/ins (n = 300) P value
Median age in yrs (25th and  
75th percentile)
11.38 (8.56–14.83) 11.23 (9.16–14.05) 11.14 (9.27–13.62)
Median zBMI (25th and  
75th percentile)
0.20 (−0.63 to 0.98) 0.35 (−0.24 to 0.97) 0.23 (−0.41 to 0.91)
Mean age at PH2+ in yrs (95% CI)
  No correction 12.65 (11.89–13.41) 12.28 (11.99–12.57) 11.97 (11.68–12.25) P = 0.043
  Corrected for zBMI 12.73 (12.00–13.46) 12.40 (12.11–12.69) 12.06 (11.79–12.33) P = 0.029
Mean age at TV >3 mL in yrs (95% CI)
  No correction 12.08 (11.49–12.67) 11.65 (11.44–11.86) 11.60 (11.39–11.81) P = 0.253
  Corrected for zBMI 12.09 (11.54–12.64) 11.79 (11.58–11.99) 11.69 (11.50–11.89) P = 0.204
n, number; yrs, years.
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P = 0.204; corrected for BMI z-score). Comparing the 
del/del as one group to the del/ins and ins/ins as another 
group did not result in a significant later age at TV > 3 mL.
The hormones FSH, E2, LH, T, DHEAS and adione 
increased with age and puberty, and SHBG decreased. No 
significant differences in hormone levels of FSH, E2, LH, 
T, SHBG, DHEAS or adione between groups corrected for 
age were observed (data not shown).
Although not statistically significant, we observed 
a higher level of DHEAS and a lower level of Adione. 
Analyzing the adione:DHEAS ratio corrected for age, we 
observed a significant lower level in the boys with the 
UGT2B17 del/del (P = 0.014).
Discussion
This is the first demonstration of delayed pubarche in 
boys carrying a common deletion of the UGT2B17 gene, 
which codes for an enzyme involved in urinary steroid 
excretion.
Knowledge is sparse regarding the genetic etiology 
of the timing of male pubertal events. However, recent 
research points to the fact that beside classical genes 
involved in central reactivation of the hypothalamic–
pituitary–gonadal axis, also genes exerting an effect on 
peripheral target tissue are significantly associated with 
the occurrence of pubertal events (17, 18). We found 
deletion of UGT2B17 to be significantly associated with 
pubarche but not with testicular enlargement >3 mL. 
The impact of UGT2B17 genotype on age at pubarche 
but not age at onset of testicular growth is in line with 
the assumption of an altered T action by UGT2B17 
affecting pubarche, a testosterone-dependent event, but 
not testicular enlargement, which is a gonadotropin-
dependent event (19). Further, our findings of an 
association of the UGT2B17 deletion with delayed 
pubarche highlight a potential role of this CNV in ethnic 
differences in timing of pubertal events. As the deletion 
is relatively rare among Caucasians and very frequent 
among Asians (1, 2), it is intriguing that although in 
Chinese boys testicular enlargement >3 mL occurs more 
than a year earlier compared to the Danish boys of our 
present study, pubarche occurs later in Chinese boys than 
in Danish boys (TV>3: 10.55 vs 11.65 years; PH2+: 12.78 
vs 12.16 years, respectively) (20). We speculate that the 
frequency of the UGT2B17 deletion may contribute to 
ethnic differences in age at pubarche.
The observed prevalence of 10% of boys being 
homozygote for the UGT2B17 deletion is in accordance 
with the prevalence in other studies of Caucasian boys 
(1, 4, 21).
In our pilot study, we found no difference in the serum 
concentration of T, but only in the urinary concentration 
of T (4). In vitro studies in prostatic cancer cells have 
revealed that both UGT2B15 and UGT2B17 are critical 
enzymes for the local inactivation of androgens (5). The 
circulating T is converted to DHT, a potent androgen 
receptor agonist, by 5α-reductase. As it is extremely 
important to modulate DHT levels locally, the substrates 
(DHT, 3α-DIOL and ADT) are regulated by steroidogenic 
enzymes and glucuronidation. Furthermore, it seems as an 
impaired clearance of T is regulated by a lower production 
of T to keep the serum level in a steady state. The lower 
production could be due to the conversion of precursors 
through other pathways than the adione to T pathway. As 
observed the boys with the UGT2B17 del/del had a lower 
adione:DHEAS ratio, indicating that the conversion of 
DHEAS to adione could be impaired.
Although some studies have observed associations 
between the deletion polymorphism of UGT2B17 with 
osteoporosis in males (2), prostate cancer (22), lower 
incidence of colorectal cancer in males (23), other studies 
observed no association with osteoporosis risk (24) or with 
risk of prostate cancer (25). A recent CNV study found 
that the UGT2B gene deletions are very common and may 
indicate that the effects are neutral or minor (26). The 
UGTB15 substitutes for UGT2B17 and other genes may 
have a compensatory role in the UGT activity.
Figure 1
Predicted probability of age at PH2+ (onset of pubic hair Tanner stage 2) 
stratified by UGT2B17 genotype.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0080
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/27/2019 12:51:24PM
via University of Copenhagen and Kobenhavns Universitet
A Mouritsen et al. UGT2B17 and pubarche 4647:3
Conclusion
UGT2B17 is involved in the timing of male pubarche. The 
boys with the homozygous deletion experienced delayed 
pubic hair development, although circulating T, DHEAS 
and androstenedione did not differ between genotype 
groups. UGT2B17 may contribute to the differential 
timing of male pubertal events across ethnicities.
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